New Ebola vaccine has been developed by scientist, according to research, the vesicular stomatitis virus (VSV)-Ebola vaccine was initiated at the Canadian National Microbiology Laboratory of the Public Health Agency of Canada.
After the trial that involved about 40 healthy people between 18 – 65 years aimed at the safety of the vaccine and the lowest possible dose required, the Canadian Immunisation Research Network (CIRN) has found that antibodies are present in participants up to six months after immunisation with the experimental VSV-Ebola vaccine.
After an injection with one of three doses, among the 40 people, 30 participants received the vaccine and 10 received placebo injections.
May ElSherif, from the Canadian Centre for Vaccinology, said: “The results of this trial were positive and very promising – all three dose levels of the VSV (vesicular stomatitis virus) Ebola vaccine were well-tolerated by participants, and no safety concerns were identified.”
It was also noted that the adverse effect of the vaccine were simple to be contend, with only three severe reactions, including headache, diarrhoea and fatigue.